Stonehage Fleming Financial Services Holdings Ltd Purchases Shares of 340,263 West Pharmaceutical Services, Inc. $WST

Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 340,263 shares of the medical instruments supplier’s stock, valued at approximately $122,154,000. West Pharmaceutical Services comprises approximately 4.2% of Stonehage Fleming Financial Services Holdings Ltd’s holdings, making the stock its 13th largest holding. Stonehage Fleming Financial Services Holdings Ltd owned 0.48% of West Pharmaceutical Services as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Addison Advisors LLC acquired a new stake in West Pharmaceutical Services in the 2nd quarter valued at approximately $28,000. Avalon Trust Co bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at $28,000. Elyxium Wealth LLC acquired a new position in West Pharmaceutical Services during the 4th quarter worth $25,000. Bayban acquired a new position in West Pharmaceutical Services during the 4th quarter worth $27,000. Finally, DV Equities LLC bought a new position in shares of West Pharmaceutical Services in the fourth quarter worth $28,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Trading Down 0.9%

Shares of West Pharmaceutical Services stock opened at $346.67 on Friday. The business has a fifty day simple moving average of $350.35 and a 200-day simple moving average of $303.37. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00. The firm has a market cap of $24.40 billion, a price-to-earnings ratio of 44.39, a price-to-earnings-growth ratio of 2.45 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is currently 11.27%.

Analysts Set New Price Targets

A number of brokerages have recently commented on WST. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Stephens reissued an “overweight” rating and set a $360.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. KeyCorp raised their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Finally, Zacks Research downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.